ClinicalTrials.gg
Active, not recruitingNCT06715124Updated Mar 2, 2026

QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

A Phase 1 interventional study of QTX3544 and Cetuximab in Advanced Solid Tumors, sponsored by Quanta Therapeutics. Active, not recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Quanta Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
237
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Quanta Therapeutics is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented, locally advanced or with KRAS G12V mutations identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic.
  • Part 1: Advanced solid tumors with at least one prior systemic therapy.
  • Evaluable and per v1.1.
  • Part 2 and 3: Measurable disease per RECIST v1.1.

Exclusion criteria

Exclusion Criteria:

  • Active or carcinomatous meningitis
  • Significant cardiovascular disease
  • Active infection requiring intravenous (IV) antibiotics
  • Prior treatment with a KRAS inhibitor

Other protocol-defined Inclusion/Exclusion Criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
237 participants (estimated)

Study arms

  • Experimental
    Part 1a: QTX3544 monotherapy dose escalation

    QTX3544 will be administered at protocol defined dose based on cohort assignment

    Drug: QTX3544

  • Experimental
    Part 1b: QTX3544 dose escalation in combination with cetuximab

    QTX3544 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment

    Drug: QTX3544 · Combination Product: Cetuximab

  • Experimental
    Part 2: QTX3544 monotherapy dose expansion

    QTX3544 will be administered at protocol defined dose based on cohort assignment

    Drug: QTX3544

  • Experimental
    Part 3: QTX3544 dose expansion in combination with cetuximab

    QTX3544 will be administered at protocol defined dose in combination with cetuximab based on cohort assignment

    Drug: QTX3544 · Combination Product: Cetuximab

Interventions

  • DrugQTX3544

    QTX3544 will be administered at protocol defined dose.

  • Combination productCetuximab

    Cetuximab will be administered at protocol defined dose.

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Define as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab.

    Time frame: up to 2 years

  2. Number of participants with Dose Limiting Toxicities (DLTs)

    DLTs will be defined as the occurrence of any of the toxicities as described in the protocol.

    Time frame: up to 21 days

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC) of QTX3544

    Plasma concentration data for QTX3544 will be used to evaluate the area under the concentration-time curve (AUC) of QTX3544.

    Time frame: up to 2 years

  2. Peak plasma concentration of QTX3544 (Cmax)

    Plasma concentration data for QTX3544 will be used to evaluate peak plasma concentration (Cmax) of QTX3544.

    Time frame: up to 2 years

  3. Objective response rate (ORR)

    The ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on RECIST 1.1.

    Time frame: up to 2 years

  4. Duration of response (DoR)

    DoR is defined as the time between first evidence of objective response and disease progression (as measured by RECIST 1.1) or death, whichever occurs earlier, in subjects who achieve CR or PR.

    Time frame: up to 2 years

07

Study locations

10 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 4, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Jan 2, 2027
CompletionEst.
Jan 2, 2029
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06715124
Lead sponsor
Quanta Therapeutics
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Jan 14, 2025
Primary completion
Jan 2, 2027 (estimated)
Completion
Jan 2, 2029 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion